Bepreve®
Bepotastine 1.5% · ophthalmic solution
Allergy
Approved uses
Ocular itching in allergic conjunctivitis
1 drop in the affected eye(s) BID
Itch relief begins within 3 minutes and persists at least 8 hours after a single drop.
OFF-LABELNot in the FDA label for this product
Vernal keratoconjunctivitis
1 drop BID, the labeled regimen, continued for 8 weeks in the cited trial
Comparative · n=50 · not sig
Single center open label comparative trial in 50 patients with vernal keratoconjunctivitis, aged 5 to 15, allocated to 1.5% solution or olopatadine 0.1% BID for 8 weeks. The authors report quicker relief of watering, ocular discomfort, and conjunctival hyperemia in the bepotastine arm but state the difference was not statistically significant; olopatadine improved papillary hypertrophy faster, and the two were equal for itching.
Contraindications
History of hypersensitivity reactions to bepotastine or any other ingredient in the formulation.
Ophthalmic solution, bepotastine besilate 15 mg/mL (1.5%), 5 mL and 10 mL LDPE dropper bottles with controlled dropper tip
Topically active, direct H1 receptor antagonist and an inhibitor of the release of histamine from mast cells. Guinea pig and in vitro models add suppression of conjunctival vascular hyperpermeability, inhibition of eosinophil infiltration into conjunctival tissue, and inhibition of eosinophil chemotaxis.
Warnings & Precautions
- Contact lens wear: Not for contact lens related irritation, and not to be instilled while lenses are worn; benzalkonium chloride 0.005% may be absorbed by soft lenses, so reinsert no sooner than 10 minutes after dosing.
- Contamination of tip and solution: To minimize contaminating the dropper tip and solution, do not touch the eyelids or surrounding areas with the dropper tip of the bottle, and keep the bottle tightly closed when not in use.
Common Side Effects
The most common reaction, in approximately 25% of subjects, was a mild taste following instillation. Eye irritation, headache, and nasopharyngitis occurred in 2% to 5% of subjects. Hypersensitivity reactions have been reported rarely during post-marketing use and may include itching, body rash, and swelling of lips, tongue and/or throat.
Pregnancy: No human data. Oral dosing of pregnant rats and rabbits through organogenesis or the pre/postnatal period produced no adverse embryofetal or offspring effects at clinically relevant systemic exposures; maternal toxicity appeared in rabbits at the lowest dose tested, 215 times the maximum recommended human ophthalmic dose on a mg/m2 basis.
Lactation: No data on presence in human milk, on the breastfed infant, or on milk production. After a single oral dose in rats, radiolabeled drug concentration in milk exceeded maternal plasma concentration at every measurement.
Safety and efficacy below age 2 not established.